Promega Corporation announced today that it has launched the ReliaPrep™ Blood and Tissue gDNA Miniprep Systems, for the extraction of high yields of very pure gDNA from even the most challenging samples, such as frozen blood. The new kits have been designed to use with small sample volumes and purify clean gDNA without ethanol, which can inhibit downstream applications.
Promega Corporation announced today the launch of the Mitochondrial ToxGlo™ Assay, a cell-based assay that enables researchers to quickly profile large compound libraries or medicinal modifications for their effects on mitochondria by allowing them to distinguish primary mitochondrial dysfunction from secondary cytotoxic events in a single well via a sequential-addition, multiplexed assay chemistry.
Promega Corporation announced today the launch of ONE-Glo™ + Tox Assay, for improved analysis of reporter gene expression in the context of cell health. The assay combines luciferase chemistry with a cell viability marker in a two-step, addition-only process, to enable measurement of cell viability and gene expression in a single well of a plate, negating the need to run parallel assays. By analyzing reporter activity in relation to cell viability, false results due to toxicity or changes in cell number can be uncovered.
Promega Corporation and ATCC (historically known as the American Type Culture Collection) have formed a partnership for the cell banking and bioproduction of cells to create a new line of bioluminescence-based drug discovery assays for biologics.
The Promega App, containing protocols, reference information and molecular biology calculators, is now available for Android. With this release, the popular Promega App is now available on both Apple and Android devices
Promega Corporation made significant progress in meeting and exceeding its 2012 environmental impact goals. The recently published Promega 2010 Corporate Responsibility Report, details all six 2012 goals and the achievement of reaching four of them by 2010.
Promega Corporation and Fugent LLC recently signed a supply agreement that establishes Promega as a provider of the leading transfection tool FuGENE® 6. This agreement ensures that researchers will continue to have access to the FuGENE® transfection reagents they have always used in their daily research. This expands on the existing Promega/Fugent agreement for supply of the FuGENE® HD Transfection reagent.
Puracyp Inc. and Promega Corporation have teamed up to provide all-inclusive kits to assess nuclear receptor activation, P450 metabolism, and cellular toxicity during the drug development process. These whole cell assay systems will identify compounds capable of activating nuclear receptors and inducing P450 metabolism while monitoring for cellular toxicity
TBM Consulting Group, the global business improvement leader for the manufacturing and service sectors, presented the Tukwila plant of Carlisle Interconnect Technologies (CIT) with the 2011 “Perfect Engine” Site Award.
TBM Consulting Group, the global business improvement leader for the manufacturing and service sectors, presented Carlisle Companies Inc. with the 2011 “Perfect Engine” award recognizing the company’s commitment to a continuous improvement philosophy and its success as a “lean” enterprise.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.